BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Steiner MA, Sciarretta C, Brisbare-Roch C, Strasser DS, Studer R, Jenck F. Examining the role of endogenous orexins in hypothalamus-pituitary-adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat. Psychoneuroendocrinology 2013;38:560-71. [PMID: 22917622 DOI: 10.1016/j.psyneuen.2012.07.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Grafe LA, Bhatnagar S. The contribution of orexins to sex differences in the stress response. Brain Res 2020;1731:145893. [PMID: 30081036 DOI: 10.1016/j.brainres.2018.07.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
2 Yeoh JW, Campbell EJ, James MH, Graham BA, Dayas CV. Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls. Front Neurosci 2014;8:36. [PMID: 24616658 DOI: 10.3389/fnins.2014.00036] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
3 Shu Q, Zhang J, Ma W, Lei Y, Zhou D. Orexin-A promotes Glu uptake by OX1R/PKCα/ERK1/2/GLT-1 pathway in astrocytes and protects co-cultured astrocytes and neurons against apoptosis in anoxia/hypoglycemic injury in vitro. Mol Cell Biochem 2017;425:103-12. [DOI: 10.1007/s11010-016-2866-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
4 Sanford LD, Suchecki D, Meerlo P. Stress, Arousal, and Sleep. In: Meerlo P, Benca RM, Abel T, editors. Sleep, Neuronal Plasticity and Brain Function. Berlin: Springer Berlin Heidelberg; 2015. pp. 379-410. [DOI: 10.1007/7854_2014_314] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 8.1] [Reference Citation Analysis]
5 Nollet M, Leman S. Role of Orexin in the Pathophysiology of Depression: Potential for Pharmacological Intervention. CNS Drugs 2013;27:411-22. [DOI: 10.1007/s40263-013-0064-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
6 James MH, Campbell EJ, Dayas CV. Role of the Orexin/Hypocretin System in Stress-Related Psychiatric Disorders. Curr Top Behav Neurosci 2017;33:197-219. [PMID: 28083790 DOI: 10.1007/7854_2016_56] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
7 Roch C, Bergamini G, Steiner MA, Clozel M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl) 2021;238:2693-708. [PMID: 34415378 DOI: 10.1007/s00213-021-05954-0] [Reference Citation Analysis]
8 Yun S, Wennerholm M, Shelton JE, Bonaventure P, Letavic MA, Shireman BT, Lovenberg TW, Dugovic C. Selective Inhibition of Orexin-2 Receptors Prevents Stress-Induced ACTH Release in Mice. Front Behav Neurosci 2017;11:83. [PMID: 28533747 DOI: 10.3389/fnbeh.2017.00083] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
9 Cohen S, Ifergane G, Vainer E, Matar MA, Kaplan Z, Zohar J, Mathé AA, Cohen H. The wake-promoting drug modafinil stimulates specific hypothalamic circuits to promote adaptive stress responses in an animal model of PTSD. Transl Psychiatry 2016;6:e917. [PMID: 27727245 DOI: 10.1038/tp.2016.172] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
10 Bonaventure P, Yun S, Johnson PL, Shekhar A, Fitz SD, Shireman BT, Lebold TP, Nepomuceno D, Lord B, Wennerholm M, Shelton J, Carruthers N, Lovenberg T, Dugovic C. A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. J Pharmacol Exp Ther 2015;352:590-601. [PMID: 25583879 DOI: 10.1124/jpet.114.220392] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
11 Perrey DA, Zhang Y. Therapeutics development for addiction: Orexin-1 receptor antagonists. Brain Res 2020;1731:145922. [PMID: 30148984 DOI: 10.1016/j.brainres.2018.08.025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
12 Cruz HG, Hay JL, Hoever P, Alessi F, te Beek ET, van Gerven JM, Dingemanse J. Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine. Eur Neuropsychopharmacol 2014;24:1257-68. [PMID: 24880753 DOI: 10.1016/j.euroneuro.2014.05.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
13 Dingemanse J, Charef P, Black J, Gouws C. Investigation of the effect of the dual orexin receptor antagonist almorexant on ophthalmological, spermatogenic, and hormonal variables in healthy male subjects. Biomed Pharmacother 2021;133:110955. [PMID: 33190032 DOI: 10.1016/j.biopha.2020.110955] [Reference Citation Analysis]
14 Navarro G, Medrano M, Aguinaga D, Vega-Quiroga I, Lillo A, Jiménez J, Casanovas M, Canela EI, Mallol J, Gysling K, Franco R. Differential effect of amphetamine over the corticotropin-releasing factor CRF2 receptor, the orexin OX1 receptor and the CRF2-OX1 heteroreceptor complex. Neuropharmacology 2019;152:102-11. [PMID: 30465812 DOI: 10.1016/j.neuropharm.2018.11.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]